Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .
Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study.
OBJECTIVE To compare the efficacies of naftopidil and tamsulosin in terms of reducing storage symptoms in patients with benign prostatic hyperplasia . MATERIAL S AND METHODS This prospect i ve r and omized study was performed at 10 centers . Ninety-four patients that had been taking tamsulosin for more than 8 weeks , but had an Overactive Bladder Symptom Score ( OABSS ) of greater than 3 points , were initially enrolled . After a 1-week washout period , patients were divided into 2 groups . Forty-five patients were treated with tamsulosin 0.2 mg daily , and 49 patients were treated with naftopidil 75 mg daily for 8 weeks . Total International Prostate Symptoms Score ( IPSS ) , storage symptom scores , nocturia times , OABSS , maximal flow rates ( Qmax ) , and postvoid residual volumes were checked before and after the 8-week treatment period . RESULTS Mean patient ages in the tamsulosin and naftopidil groups were 64.8 and 66.0 years , respectively . Baseline characteristics were not significantly different . In the tamsulosin group , mean total IPSS decreased from 19.1 to 15.1 after the 8-week treated period ( P = .001 ) , and in the naftopidil group , mean total IPSS decreased from 16.9 to 13.1 ( P = .001 ) . Mean storage symptom scores were reduced in the tamsulosin and naftopidil groups from 8.0 to 6.6 ( P = .002 ) and from 7.6 to 6.1 ( P = .001 ) , respectively . Mean nocturia times in the naftopidil groups decreased significantly from 2.5 to 1.9 ( P = .001 ) , and mean OABSSs were reduced from 7.7 to 6.0 ( P = .001 ) and from 7.4 to 6.0 ( P = .001 ) , respectively . CONCLUSION Total IPSS , storage symptom scores , nocturia times , and OABSS were significantly reduced by naftopidil and tamsulosin . Moreover , the naftopidil group showed better improvements in nocturia than the tamsulosin group
Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .